Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 946-573-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://chesar.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 04-18 July 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- GLP study conducted in compliance with OECD guideline 429 with minor deviations: temperature was sometimes outside of the target ranges
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
- Report date:
- 2012
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- dated 22 July 2010
- Deviations:
- yes
- Remarks:
- temperature was sometimes outside of the target ranges
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- dated 30 May 2008
- Deviations:
- yes
- Remarks:
- temperature was sometimes outside of the target ranges
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- 20 March 2009
- Type of study:
- mouse local lymph node assay (LLNA)
Test material
- Reference substance name:
- Resinoid of Styrax tonkinensis (Styracaceae) obtained from exudate by ethanol extraction
- EC Number:
- 946-573-9
- IUPAC Name:
- Resinoid of Styrax tonkinensis (Styracaceae) obtained from exudate by ethanol extraction
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Lot/batch No.of test material: VE00201963
- Expiration date of the lot/batch: 21 March 2014
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: At room temperature and protected from light
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- CBA
- Remarks:
- CBA/CaOlaHsd
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Harlan Laboratories B.V., The Netherlands
- Females (if applicable) nulliparous and non-pregnant: Yes
- Age at study initiation: 8-10 weeks
- Weight at study initiation: 20.9 ± 1.2 g
- Housing: Animals were housed in groups of five in Makrolon Type II / III cages, with wire mesh top.
- Diet: 2018C Teklad Global 18% protein rodent diet (certified), ad libitum
- Water: Tap water, ad libitum
- Acclimation period: At least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature: 22 ± 2°C
- Humidity: 45-65% (>95% for several hours)
- Photoperiod: 12 hours dark / 12 hours light
Study design: in vivo (LLNA)
- Vehicle:
- dimethylformamide
- Concentration:
- 0, 10, 25 and 50% (w/w)
- No. of animals per dose:
- 5 females per dose
- Details on study design:
- PRE-SCREEN TESTS:
- Vehicle selection: In the solubility experiment, the highest test item concentration, which could be technically used, was a 50% solution in dimethylsulfoxide. Vortexing was used to formulate the test item. At higher concentrations, an applicable formulation of the test item was not achieved, neither by the use of other vehicles nor by using additional methods to formulate the test item (e.g. sonicating, warming to 37°C).
- Dose selection: Two mice were treated by (epidermal) topical application to the dorsal surface of each ear with test item concentrations of 25 and 50% (w/w) once daily each on three consecutive days. Prior to the first application of the test item and before sacrifice the body weight was determined. Clinical signs were recorded at least once daily. Eventual signs of local skin irritation were documented and a score was used to grade a possible erythema of the ear skin. Furthermore, prior to the first application of the test item (on Day 1), on Day 3 and before sacrifice (on Day 6) the ear thickness was determined using a micrometer. Additionally, for both animals, the ears were punched after sacrifice (Day 6) at the apical area using a biopsy punch and were immediately pooled per animal and weighed using an analytical balance. Eventual ear irritation was considered to be excessive if an erythema of the ear skin of a score value >=3 was observed at any observation time and/or if an increase in ear thickness of >=25% was recorded on Day 3 or Day 6. At the tested concentrations the animals did not show any signs of local skin irritation or systemic toxicity. Thus, the test item in the main study was assayed at 10, 25, and 50% (w/w). The highest concentration tested was the highest level that could be achieved whilst avoiding systemic toxicity and excessive local skin irritation in the pre-experiment.
MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method: Local Lymph Node Assay (LLNA)
- Criteria used to consider a positive response: A test item is regarded as a sensitiser in the LLNA if the following criteria are fulfilled:
First, that exposure to at least one concentration of the test item resulted in an incorporation of 3HTdR at least 3-fold or greater than that recorded in control mice, as indicated by the Stimulation Index.
Second, that the data are compatible with a conventional dose response, although allowance must be made (especially at high topical concentrations) for either local toxicity or immunological suppression.
TREATMENT PREPARATION AND ADMINISTRATION: Each test group of mice was treated by topical (epidermal) application to the dorsal surface of each ear with different test item concentrations of 10, 25, and 50% (w/w) in dimethylformamide. The application volume, 25 µL/ear/day, was spread over the entire dorsal surface of each ear once daily for three consecutive days. A further group of mice was treated with an equivalent volume of the relevant vehicle alone (control animals). Five days after the first topical application (Day 6) 250 µL of phosphate-buffered saline (PBS) containing 19.5 µCi of 3HTdR (equivalent to 3HTdR 78 µCi/mL) were injected into each test and control mouse via the tail vein. Approximately five hours after treatment with 3HTdR all mice were euthanised by intraperitoneal injection of Pentobarbital-Sodium. The draining lymph nodes were rapidly excised and pooled per animal (2 nodes per animal). Single cell suspensions of lymph node cells were prepared from pooled lymph nodes, which were subsequently washed and incubated with trichloroacetic acid overnight. The level of 3HTdR incorporation, expressed as as the number of radioactive disintegrations per minute (DPM), was then measured on a β-scintillation counter (Tricarb 2900 TR, Perkin Elmer (LAS) GmbH, 63110 Rodgau, Germany). The proliferative response of the lymph node cells was expressed as the number of radioactive disintegrations per minute per lymph nodes of each animal (DPM/animal) and as the ratio of 3HTdR incorporated into lymph node cells of lymph nodes of test animals relative to that recorded for lymph nodes of control animals (Stimulation Index; S.I.). Before DPM/animal values were determined, mean scintillation-background DPM was subtracted from test and control raw data. - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Statistics:
- For all statistical calculations SigmaStat for Windows (Version 2.0) was used.
A One-Way-Analysis-of-Variance (ANOVA) was conducted on the ear weights to assess whether the difference was statistically significant between test item groups and negative control (vehicle) group. Furthermore, the ANOVA was conducted on the ear thickness values to assess whether a statistically significant increase in ear thickness could be observed when comparing the values measured on Day 1 prior to application with the values measured on Days 3 or 6 in the respective test item groups or within the vehicle control group. Statistical significance was set at the 5% level (p < 0.05).
The Dean-Dixon-Test was used for identification of possible outliers (performed with Microsoft Excel 2003). However, both biological and statistical significance were considered together.
Results and discussion
- Positive control results:
- In the historical study performed in April 2012 on positive control (Hexylcinnamaldehyde), S.I. values were 1.00, 0.88, 1.51 and 3.73 at the concentrations of 0, 5, 10 and 25% (w/v), and EC3 value was 20.1% (w/v). The study was therefore considered valid.
In vivo (LLNA)
Resultsopen allclose all
- Key result
- Parameter:
- EC3
- Remarks:
- in % (w/w)
- Value:
- ca. 4.8
- Remarks on result:
- other: considered as a moderate skin sensitizer
- Parameter:
- SI
- Value:
- 5.28
- Test group / Remarks:
- at the tested concentration of 10%
- Parameter:
- SI
- Value:
- 8.22
- Test group / Remarks:
- at the tested concentration of 25%
- Parameter:
- SI
- Value:
- 9.02
- Test group / Remarks:
- at the tested concentration of 50%
- Cellular proliferation data / Observations:
- DETAILS ON STIMULATION INDEX CALCULATION
In the proliferation assay, the observed SI values were 1.00, 5.28, 8.22 and 9.023 at 0, 10, 25 and 50%, respectively. A clear dose response was observed. Refer tables 7.4.1/1 and 7.4.1/2 for details.
EC3 CALCULATION
An estimated EC3 value was determined by means of extrapolation from the two lowest test item concentrations and their respective Stimulation Indices. This extrapolated EC3 value was calculated as 4.8% (w/w).
MORTALITY / CLINICAL OBSERVATIONS:
No clinical signs and no mortality were observed during the study.
BODY WEIGHTS
The body weight gain of the treated animals was within the normal range.
LOCAL IRRITATION
On Days 2-6, the animals treated with a test item concentration of 50% showed a very slight to well defined erythema of the ear skin (Days 2, 3, 4, 6: Score 1; Day 5: Score 2).
EAR THICKNESS /EAR WEIGHT
A relevant increase in ear thickness was not observed.
Any other information on results incl. tables
Table 7.4.1/1: Skin sensitization – results
Test item concentration |
DPM values measured |
DPM-BG per animal (2 lymph nodes)a) |
S.I.b) |
||
% (w/w) |
Group no. |
Animal no. |
|||
--- |
--- |
BG I |
17 |
--- |
--- |
--- |
--- |
BG II |
16 |
--- |
--- |
0 |
1 |
1 |
484 |
467 |
--- |
0 |
1 |
2 |
1343 |
1326 |
--- |
0 |
1 |
3 |
907 |
890 |
--- |
0 |
1 |
4 |
1099 |
1082 |
--- |
0 |
1 |
5 |
441 |
424 |
--- |
10 |
2 |
6 |
6317 |
6300 |
7.5 |
10 |
2 |
7 |
5333 |
5316 |
6.3 |
10 |
2 |
8 |
4028 |
4011 |
4.8 |
10 |
2 |
9 |
3261 |
3244 |
3.9 |
10 |
2 |
10 |
3276 |
3259 |
3.9 |
25 |
3 |
11 |
8427 |
8410 |
10.0 |
25 |
3 |
12 |
8265 |
8248 |
9.8 |
25 |
3 |
13 |
5216 |
5199 |
6.2 |
25 |
3 |
14 |
5185 |
5168 |
6.2 |
25 |
3 |
15 |
7455 |
7438 |
8.9 |
50 |
4 |
16 |
7502 |
7485 |
8.9 |
50 |
4 |
17 |
9122 |
9105 |
10.9 |
50 |
4 |
18 |
9397 |
9380 |
11.2 |
50 |
4 |
19 |
6004 |
5987 |
7.1 |
50 |
4 |
20 |
5853 |
5836 |
7.0 |
BG = Background (1 mL 5% trichloroacetic acid) in duplicate
1 = Control Group
2-4 = Test Groups
S.I. = Stimulation Index
a)= values corrected for mean background value (BGI and BGII).
b)= Stimulation Indices relative to the mean of the control group (Group 1)
Table 7.4.1/2: Calculation of Stimulation Indices per Dose Group
Test item concentration |
Group Calculation |
||
Mean DPM per animal (2 lymph nodes)a) |
SDb) |
S.I. |
|
Vehicle (dimethylformamide) |
838.3 |
390.3 |
1.00 |
10% Test item |
4426.5 |
1344.9 |
5.28 |
25% Test item |
6893.1 |
1603.1 |
8.22 |
50% Test item |
7559.1 |
1669.7 |
9.02 |
a)Mean DPM/animal was determined by dividing the sum of the measured values from lymph nodes of all animals within a group by the number of animals in that group (5 animals)
b)SD = stimulation index
Table 7.4.1/3: Calculation of the EC3 Value by Means of Extrapolation
S.I. |
||
Concentration |
25% (a) |
8.2 (b) |
Concentration |
10% (c) |
5.3 (d) |
EC3 = 2(log2 (c) + (3-d) / (b-d) * (log2(a) - log2(c))) |
||
EC3 |
4.8% |
3.0 |
EC3 = Estimated concentration for a S.I. of 3.
a,b,c,d = Co-ordinates of the two pairs of data lying immediately above the S.I. value of 3 on the LLNA dose response plot. The point with the higher S.I. is denoted as (a, b). The point with the lower S.I. is denoted as (c, d).
Applicant's summary and conclusion
- Interpretation of results:
- Category 1B (indication of skin sensitising potential) based on GHS criteria
- Conclusions:
- Under these test conditions, the test item was considered as a moderate skin sensitizer (i.e. EC3 >2%) and need to be classified as "Category 1 and sub-category 1B" according to the Regulation (EC) N° 1272/2008 and according to the Globally Harmonised System of classification and labelling of chemicals (GHS). The hazard statement "H317: may cause an allergic skin reaction" with the symbol “exclamation mark” and signal word "Warning" are required.
- Executive summary:
In a Local Lymph Node Assay (LLNA) performed according to OECD Guideline 429 and in compliance with GLP, groups of CBA/CaOlaHsd mice (5 females/dose) were topically applied with 25 µL/ear/day of test item at concentrations of 10, 25 and 50% (w/w) in dimethylformamide to the dorsal surface of both ears for three consecutive days (Days 1, 2 and 3). One negative control group of five animals received the vehicle (dimethylformamide). Five days after the first topical application the mice were injected intravenously into a tail vein with radio-labelled thymidine (3H-methyl thymidine). Approximately five hours after intravenous injection, the mice were sacrificed, the draining auricular lymph nodes excised and pooled per animal. Single cell suspensions of lymph node cells were prepared from pooled lymph nodes, which were subsequently washed and incubated with trichloroacetic acid overnight. The proliferative capacity of pooled lymph node cells was determined by the incorporation of 3H-methyl thymidine measured in a β-scintillation counter. The highest concentration tested was the highest concentration that could be achieved whilst avoiding systemic toxicity and excessive local skin irritation as confirmed by a pre-experiment.
All treated animals survived the scheduled study period and no signs of systemic toxicity were observed. On Days 2-6, the animals treated with a test item concentration of 50% showed an erythema of the ear skin (Days 2, 3, 4, 6: Score 1; day 5: Score 2). No statistically significant increases in ear thickness or ear weights were observed.
In this study, Stimulation Indices (S.I.) of 1.00, 5.28, 8.22 and 9.02 were determined with the test item at concentrations of 0, 10, 25, and 50% (w/w) in dimethylformamide. A clear dose response was observed. An estimated EC3 value was determined by means of extrapolation from the two lowest test item concentrations and their respective S.I. This extrapolated EC3 value was calculated as 4.8% (w/w).
In the historical study performed on positive control (Hexylcinnamaldehyde), S.I. values were 1.00, 0.88, 1.51 and 3.73 at the concentrations of 0, 5, 10 and 25% (w/v), and EC3 value was 20.1% (w/v). The study was therefore considered valid.
Under these test conditions, the test item was considered as a moderate skin sensitizer (i.e. EC3 >2%) and need to be classified as "Category 1 and sub-category 1B" according to the Regulation (EC) N° 1272/2008 and according to the Globally Harmonised System of classification and labelling of chemicals (GHS). The hazard statement "H317: may cause an allergic skin reaction" with the symbol “exclamation mark” and signal word "Warning" are required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)